These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31854272)

  • 1. Biologic Therapy in Crohn's Disease-What We Have Learnt So Far.
    Majchrzak K; Fichna J
    Curr Drug Targets; 2020; 21(8):792-806. PubMed ID: 31854272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of biologic therapy for Crohn's disease.
    Dryden GW
    Expert Opin Biol Ther; 2009 Aug; 9(8):967-74. PubMed ID: 19591627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
    Brookes MJ; Green JR
    Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.
    Berns M; Hommes DW
    Expert Opin Investig Drugs; 2016; 25(2):129-43. PubMed ID: 26616476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of biological therapy in pediatric patients with Crohn's disease.
    Tarnok A; Kiss Z; Kadenczki O; Veres G
    Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients.
    Lightner AL; Grass F; Alsughayer AM; Harmsen WS; Petersen M; Loftus EV
    Dis Colon Rectum; 2020 Jul; 63(7):934-943. PubMed ID: 32149787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
    Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T
    Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440
    [No Abstract]   [Full Text] [Related]  

  • 16. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
    Zheng MK; Shih DQ; Chen GC
    World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "New drugs: kids come first": children should be included in trials of new biological treatments.
    Cucchiara S; Morley-Fletcher A
    Inflamm Bowel Dis; 2007 Sep; 13(9):1165-9; discussion 1176-7. PubMed ID: 17455208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
    Deiana S; Gabbani T; Annese V
    World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.